Table 1.

Patient characteristics at diagnosis

MDS (n = 143)MDS/MPN (n = 51)
Gender, male73 (51.0%)36 (70.6%)
Age, mean (range)64.8 [15.5–88.6]67.5 (36.4–87.0)
Etiology
De novo118 (82.5%)47 (92.2%)
 Secondary (treatment-related)25 (17.5%)4 (7.8%)
WHO MDS classification
 MDS-SLD20 (14.0%)
 MDS-MLD33 (23.1%)
 MDS-RS16 (11.2%)
 MDS-EB-125 (17.5%)
 MDS-EB-235 (24.5%)
 MDS with isolated del(5q)10 (7.0%)
 MDS-U4 (2.8%)
WHO MDS/MPN classification
 CMML35 (68.6%)
 MDS/MPN-U16 (31.4%)
Survival status 2 years after diagnosis
 Alive60 (42.0%)32 (62.7%)
 Deceased70 (49.0%)19 (37.3%)
 Not defined or censored due to alloHSCT13 (9.1%)0 (0.0%)
Progression to AML within 2 years of diagnosis
 No51 (35.7%)28 (54.9%)
 Yes42 (29.4%)11 (21.6%)
 Not defined or censored due to alloHSCT50 (35.0%)12 (23.5%)
Azacytidine-treated within 1 year of diagnosis
 No78 (54.5%)31 (60.8%)
 Yes65 (45.5%)20 (39.2%)
IPSS risk class
 Low24 (16.8%)
 Intermediate-157 (39.9%)
 Intermediate-226 (18.2%)
 High24 (16.8%)
 Not defined12 (8.4%)
IPSS-R risk class
 Very low17 (11.9%)
 Low33 (23.1%)
 Intermediate27 (18.9%)
 High26 (18.2%)
 Very high28 (19.6%)
 Not defined12 (8.4%)
AlloHSCT
 No117 (81.8%)43 (84.3%)
 Yes24 (16.8%)8 (15.7%)
 Not defined2 (1.4%)0 (0.0%)
  • Abbreviations: alloHSCT, allogeneic hematopoietic stem cell transplantation; MDS-EB-1, MDS with excess blasts 1; MDS-EB-2, MDS with excess blasts 2; MDS-MLD, MDS with multilineage dysplasia; MDS/MPN-U, MDS/MPN, unclassifiable; MDS-RS, MDS with ring sideroblasts; MDS-SLD, MDS with single-lineage dysplasia; MDS-U, MDS, unclassifiable.